Loading
Nintedanib is a triple angiokinase inhibitor pill (VEGFR, FGFR, PDGFR) approved for pulmonary fibrosis and, in the EU, for second-line lung adenocarcinoma with docetaxel. In mesothelioma the phase 2 part of LUME-Meso suggested slower progression in epithelioid disease, but the phase 3 part showed none, a much-cited warning about small randomised phase 2 signals.
Nintedanib is a triple angiokinase inhibitor of VEGFR1-3, FGFR1-3 and PDGFR alpha and beta, designed to cut off tumour blood supply and stromal signalling. It is approved for idiopathic pulmonary fibrosis and, in the EU, for second-line lung adenocarcinoma with docetaxel. In mesothelioma, the LUME-Meso phase 2 suggested a PFS benefit in epithelioid disease, but the phase 3 part of the same trial showed none, with PFS 6.8 versus 7.0 months (HR 1.01) and no OS benefit. The programme is a frequently cited lesson in how unreliable small randomised phase 2 PFS signals can be in this disease. Boehringer Ingelheim developed it, and its oncology role is now limited to the EU lung indication. A plausible mechanism and an encouraging early trial are not enough until a large trial confirms them.
Triple angiokinase inhibitor of VEGFR1-3, FGFR1-3, PDGFRα/β. Connects to VEGF / VEGFR and FGFR2.
1.Blocks VEGFR, FGFR, and PDGFR signalling in endothelial and stromal cells
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| EU | 2014 | Adenocarcinoma NSCLC after first-line chemotherapy, with docetaxel |
| US | 2014 | Idiopathic pulmonary fibrosis (non-oncology) |
| England (NICE) | 2015 | Locally advanced, metastatic or locally recurrent non-small-cell lung cancer of adenocarcinoma histology progressing after first-line chemotherapy, with docetaxel · TA347, published 22 July 2015, with the discount agreed in the patient access scheme. |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Nintedanib" OR ABSTRACT:"Nintedanib" OR TITLE:"Ofev" OR ABSTRACT:"Ofev" OR TITLE:"fibrosis ; Vargatef" OR ABSTRACT:"fibrosis ; Vargatef" OR TITLE:"NSCLC" OR ABSTRACT:"NSCLC") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Nintedanib, not a curated reading list.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag failure.
Shares Small-molecule kinase inhibitors and the tag failure.
Shares Small-molecule kinase inhibitors and the tag failure.
Shares Small-molecule kinase inhibitors and the tag failure.
Shares Small-molecule kinase inhibitors and the tag failure.
Shares LUME-Lung 1, Adenocarcinoma of the lung, VEGF / VEGFR, Anti-angiogenic therapy.
Shares VEGF / VEGFR, Mesothelioma, Anti-angiogenic therapy.
Shares Boehringer Ingelheim, Adenocarcinoma of the lung, Lung cancer (all types), Small-molecule kinase inhibitors.